Microenvironmental interleukin-6 suppresses toll-like receptor signaling in human leukemia cells through miR-17/19A

Blood

Volumn 126, Issue 6, 2015, Pages 766-778

  Li, Yanmei ^a   Shi, Yonghong ^a   McCaw, Lindsay ^a   Li, You Jun ^a,b   Zhu, Fang ^c,d   Gorczynski, Reg ^c,d   Duncan, Gordon S ^e   Yang, Burton ^a,f   Ben David, Yaacov ^g   Spaner, David E ^a,c  

^a Canada   (Canada)

^b Basic Medical College   (China)

^c UNIVERSITY OF TORONTO   (Canada)

^d TORONTO GENERAL HOSPITAL   (Canada)

^e PRINCESS MARGARET HOSPITAL   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; JANUS KINASE INHIBITOR; MESSENGER RNA; MICRORNA; MICRORNA 17; MICRORNA 19A; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IL6 PROTEIN, HUMAN; JANUS KINASE 1; MIRN17 MICRORNA, HUMAN; MIRN17-92 MICRORNA, HUMAN; MIRN19 MICRORNA, HUMAN; NEUTRALIZING ANTIBODY; OLIGONUCLEOTIDE; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; TLR7 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; STROMA CELL; TUMOR MICROENVIRONMENT; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; B LYMPHOCYTE; BIOSYNTHESIS; COCULTURE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; NONOBESE DIABETIC MOUSE; PATHOLOGY; SCID MOUSE; SECRETION (PROCESS); TUMOR CELL LINE;

ANIMALS; ANTIBODIES, NEUTRALIZING; B-LYMPHOCYTES; CELL LINE, TUMOR; COCULTURE TECHNIQUES; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-6; JANUS KINASE 1; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; MICE, INBRED NOD; MICE, SCID; MICRORNAS; OLIGONUCLEOTIDES; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; STROMAL CELLS; TOLL-LIKE RECEPTOR 7; TUMOR MICROENVIRONMENT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84940031281     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-12-618678     Document Type: Article

References (47)

1. Wiestner A. Targeting B-cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol. 2013;31(1):128-130.
2. Puente XS, Pinyol M, Quesada V, et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature. 2011;475(7354):101-105.
3. Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program. 2011;2011:96-103.
4. Tomic J, Lichty B, Spaner DE. Aberrant interferon-signaling is associated with aggressive chronic lymphocytic leukemia. Blood. 2011;117(9):2668-2680.
5. Muzio M, Scielzo C, Bertilaccio MT, Frenquelli M, Ghia P, Caligaris-Cappio F. Expression and function of toll like receptors in chronic lymphocytic leukaemia cells. Br J Haematol. 2009;144(4):507-516.
6. Spaner DE, Masellis A. Toll-like receptor agonists in the treatment of chronic lymphocytic leukemia. Leukemia. 2007;21(1):53-60.
7. Spaner DE, Shi Y, White D, et al. Immunomodulatory effects of toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia. 2006;20(2):286-295.
8. Shi Y, White D, He L, Miller RL, Spaner DE. Toll-like receptor-7 tolerizes malignant B cells and enhances killing by cytotoxic agents. Cancer Res. 2007;67(4):1823-1831.
9. Spaner DE, Miller RL, Mena J, Grossman L, Sorrenti V, Shi Y. Regression of lymphomatous skin deposits in a chronic lymphocytic leukemia patient treated with the toll-like receptor-7/8 agonist, imiquimod. Leuk Lymphoma. 2005;46(6):935-939.
10. Spaner DE, Shi Y, White D, et al. A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia. Leukemia. 2010;24(1):222-226.
11. Hamilton E, Pearce L, Morgan L, et al. Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. Br J Haematol. 2012;158(5):589-599.
12. Plander M, Seegers S, Ugocsai P, et al. Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Leukemia. 2009;23(11):2118-2128.
13. Ding W, Knox TR, Tschumper RC, et al. Plateletderived growth factor (PDGF)-PDGF receptor interaction activates bone marrow-derived mesenchymal stromal cells derived from chronic lymphocytic leukemia: implications for an angiogenic switch. Blood. 2010;116(16):2984-2993.
14. Hallek M, Cheson BD, Catovsky D, et al International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of CLL: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
15. Wong KK, Brenneman F, Chesney A, Spaner DE, Gorczynski RM. Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice. Cancer Res. 2012;72(19):4931-4943.
16. Tomic J, White D, Shi Y, et al. Sensitization of IL-2 signaling through TLR-7 enhances B lymphoma cell immunogenicity. J Immunol. 2006;176(6):3830-3839.
17. Spaner D, Raju K, Radvanyi L, Lin Y, Miller RG. A role for perforin in activation-induced cell death. J Immunol. 1998;160(6):2655-2664.
18. Shaha SP, Tomic J, Shi Y, et al. Prolonging microtubule dysruption enhances the immunogenicity of chronic lymphocytic leukaemia cells. Clin Exp Immunol. 2009;158(2):186-198.
19. Emeagi PU, Maenhout S, Dang N, Heirman C, Thielemans K, Breckpot K. Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy. Gene Ther. 2013;20(11):1085-1092.
20. Tung S, Shi Y, Wong K, et al. PPARα and fatty acid oxidation mediate glucocorticoid resistance in chronic lymphocytic leukemia. Blood. 2013;122(6):969-980.
21. rd ed. Baltimore, MD: Sparky House Publishing; 2013.
22. Sidney LE, Branch MJ, Dunphy SE, Dua HS, Hopkinson A. Concise review: evidence for CD34 as a common marker for diverse progenitors. Stem Cells. 2014;32(6):1380-1389.
23. Zhang W, Kater AP, Widhopf GF II, et al. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci USA. 2010;107(44):18956-18960.
24. Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14(11):736-746.
25. Pattison MJ, Mackenzie KF, Arthur JS. Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback. J Immunol. 2012;189(6):2784-2792.
26. Bomben R, Gobessi S, Dal Bo M, et al. The miR-17-92 family regulates the response to toll-like receptor 9 triggering of CLL cells with unmutated IGHV genes. Leukemia. 2012;26(7):1584-1593.
27. Efremov DG, Bomben R, Gobessi S, Gattei V. TLR9 signaling defines distinct prognostic subsets in CLL. Front Biosci (Landmark Ed). 2013;18:371-386.
28. Fan H, Cook JA. Molecular mechanisms of endotoxin tolerance. J Endotoxin Res. 2004;10(2):71-84.
29. Li Y, Vecchiarelli-Federico LM, Li YJ, et al. The miR-17-92 cluster expands multipotent hematopoietic progenitors whereas imbalanced expression of its individual oncogenic miRNAs promotes leukemia in mice. Blood. 2012;119(19):4486-4498.
30. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell. 2008;133(2):217-222.
31. Nagase H, Okugawa S, Ota Y, et al. Expression and function of toll-like receptors in eosinophils: activation by toll-like receptor 7 ligand. J Immunol. 2003;171(8):3977-3982.
32. Brock M, Trenkmann M, Gay RE, et al. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Circ Res. 2009;104(10):1184-1191.
33. Dai B, Meng J, Peyton M, et al. STAT3 mediates resistance to MEK inhibitor through microRNA miR-17. Cancer Res. 2011;71(10):3658-3668.
34. Lin HY, Chiang CH, Hung WC. STAT3 upregulates miR-92a to inhibit RECK expression and to promote invasiveness of lung cancer cells. Br J Cancer. 2013;109(3):731-738.
35. Martínez-Trillos A, Pinyol M, Navarro A, et al. Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome. Blood. 2014;123(24):3790-3796.
36. Ntoufa S, Vardi A, Papakonstantinou N, et al. Distinct innate immunity pathways to activation and tolerance in subgroups of chronic lymphocytic leukemia with distinct immunoglobulin receptors. Mol Med. 2012;18:1281-1291.
37. Yoon JY, Lafarge S, Dawe D, et al. Association of interleukin-6 and interleukin-8 with poor prognosis in elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2012;53(9):1735-1742.
38. Levidou G, Sachanas S, Pangalis GA, et al. Immunohistochemical analysis of IL-6, IL-8/CXCR2 axis, (Tyr)p-STAT-3, and SOCS-3 in lymph nodes from patients with CLL: correlation between microvascular characteristics and prognostic significance. Biomed Res Int. 2014;2014:251479.
39. Calissano C, Damle RN, Marsilio S, et al. Intraclonal complexity in chronic lymphocytic leukemia: fractions enriched in recently born/divided and older/quiescent cells. Mol Med. 2011;17(11-12):1374-1382.
40. Mauer J, Chaurasia B, Goldau J, et al. Signaling by IL-6 promotes alternative activation of macrophages to limit endotoxemia and obesity-associated resistance to insulin. Nat Immunol. 2014;15(5):423-430.
41. Herishanu Y, Pérez-Galán P, Liu D, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood. 2011;117(2):563-574.
42. Jin HY, Oda H, Lai M, et al. MicroRNA-17-92 plays a causative role in lymphomagenesis by coordinating multiple oncogenic pathways. EMBO J. 2013;32(17):2377-2391.
43. Aderka D, Maor Y, Novick D, et al. Interleukin-6 inhibits the proliferation of B-chronic lymphocytic leukemia cells that is induced by tumor necrosis factor-alpha or -beta. Blood. 1993;81(8):2076-2084.
44. Marotta LL, Almendro V, Marusyk A, et al. The JAK2/STAT3 signaling pathway is required for growth of CD44+CD242 stem cell-like breast cancer cells in human tumors. J Clin Invest. 2011;121(7):2723-2735.
45. Grabner B, Schramek D, Mueller KM, et al. Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nat Commun. 2015;6:6285.
46. Sansone P, Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J Clin Oncol. 2012;30(9):1005-1014.
47. Temburni S, Barrientos J, Kolitz J, et al. Ibrutinib inhibits concomitant TLR and BCR-driven proliferation of CLL cells and overrides the supportive survival-promoting effects of microenvironmental signals [abstract]. Blood (ASH Annual Meeting Abstracts). 2014;124(21). Abstract 3310.